Maggie L. Shaw

The effect of education on survival outcomes was evaluated both overall and as it related to cardiovascular disease (CVD).

Jeff Hunnicutt, CEO of Highlands Oncology Group, discusses the difference between business intelligence and artificial intelligence (AI), including process implementation and data compilation.

Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic, addresses several reasons that have potential to delay a correct multiple sclerosis (MS) diagnosis in minority patient populations, including social determinants of health.

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Precision medicine starts with the patient-physician relationship, and this also involves an entire care team, emphasized Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

Causes of heart failure (HF), medication usage, and HF-related hospitalization and death were investigated among patients from 40 countries and 4 economic levels.

Individuals living with heart failure in the United States are expected to top 8 million by 2030 vs the close to 6 million living with the disease between 2015 and 2018.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

Many adolescents and young adults (AYAs) with advanced heart disease prefer to be involved in decisions that have an impact on their medical care, but new survey results show there is a great need for educational communication efforts that involve their caregivers and clinicians.

The behavioral economic biases of 43 African American young adults aged 18 to 24 were evaluated on 4 fronts: present bias, information salience, overoptimism, and loss aversion.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.

Dupilumab treatment delivered at a specialized tertiary care center has great potential to improve patient clinical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP).

Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

Study investigators stress the importance of health care professionals familiarizing themselves with risk factors among a more diverse patient population.

This subanalysis of data from the VIRGO study encompassed 2979 patients who had an acute myocardial infarction (AMI), or heart attack, between ages 18 and 55 years; outcomes evaluated included all-cause and cause-specific acute events requiring hospitalization in the year after discharge for a heart attack.

It is likely that social determinants of health (SDOH) may affect the differences in outcomes from multiple sclerosis (MS) that we see among Black/African American and Hispanic/Latinx populations, absent more data on their genetics and ancestry, noted Mitzi Joi Williams, MD, FAAN.

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

The potential ethical implications for goals of care discussions between surrogate decision makers and health care providers concerning patients who reside in a state of cognitive motor dissociation were investigated in this new study from a team at Columbia University and New York Presbyterian Hospital.

Much more work needs to be done surrounding multiple sclerosis (MS) and treating pregnant patients safely, noted Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic.

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.

Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

There are limited data on potential disparities in dementia medication use in the outpatient setting, with study authors highlighting that the benefits of these medications are not equitably distributed along racial and ethnic lines because of usage differences.

A study from investigators in the Quantitative Health Science, Neurology, and Radiology departments of Mayo Clinic investigated if and how social and structural determinants of health (SSDOH) might influence mild cognitive impairment and/or risk of dementia among participants of the Mayo Clinic Study of Aging.

Terminology and concepts relevant to the care of transgender and gender-diverse individuals and best practices for optimizing neurologic care in this patient population were covered in the session “Neurologic Conditions in Transgender Patients” on Sunday, April 23, at the American Academy of Neurology annual meeting.

A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.

The investigators of this study wanted to know if hospitals that cared for a high proportion of Black patients delivered care for heart failure (HF) that differed in quality from that provided by other hospitals.

In several abstracts presented at this year's American Academy of Neurology Annual Meeting, Mitzi Joi Williams, MD, FAAN, Joi Life Wellness Neurology Clinic, explores multiple sclerosis–related outcomes in diverse patient populations.

Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.

For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.